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Introduction 
 
• Atheromatous plaques can be classified in two main 
types: stable and unstable.  
 
• Unstable plaques often show plaque angiogenesis 
and are prone to rupture, promoting thrombus 
formation which can lead to a myocardial infarction, 
stroke, and sudden death1.  
 
• Inhibition of intraplaque angiogenesis is a strategy 
to reduce atherosclerotic plaque size and stabilize 
the plaques. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE CURRENT PROJECT 
 
Use anti-angiogenic strategies to prevent intraplaque 
angiogenesis studying the effects of the inhibition of 
bFGF (using K5) and PFKFB3 (using AZ33) on plaque 
angiogenesis. 
MATERIAL AND METHODS 
 
 
 
CONCLUSIONS 
 
In vitro inhibition of  bFGF and inhibition of 
glycolysis resulted in a lower migration and 
proliferation of ECs, and the inhibition of PFKFB3 
showed also ability an impaired formation on new 
vessels. 
Inhibition of bFGF and PFKFB3, via targeting 
molecules, are two promising strategies to prevent 
intraplaque angiogenesis and increase plaque 
stability. 
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Figure A. K5 is able to reduce migration of ECs cells in a scratch migration assay and Figure B. is also able to reduce 
proliferation of ECs measured in an MTT assay.   
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Figure A. In a scratch migration assay  using H5V cells, AZ33  resulted able to inhibit the capacity of ECs to migrate and in 
Figure B. resulted also able to inhibit ECs proliferation evaluated as the OD resultant value of an MTT assay. Figure C. In an 
aortic ring assay AZ33 inhibited the formation of neovessels at  concentrations of 40µM (Figure C 3) and 80 µM (Figure C 4) 
compared to the control (Figure C 1), while lower concentration  didn’t show any effect (Figure C 2). 
A B 
C 
1 2 3 4 
INHIBITION OF bFGF 
K5 is a molecule able to bind the angiogenic growth factor bFGF, to block its interaction with the receptors on the surface 
of endothelial cells and block its biological activity. The anti-angiogenic effects of this compound were measured as the 
ability to stimulate the proliferation  and migration of ECs. 
INHIBITION OF GLYCOLYSIS 
In angiogenesis endothelial cells rely of glycolysis and PFKFB3 is a key enzyme in this metabolic pathway. AZ33 is a selective 
inhibitor of the kinase part of the PFKFB3 enzyme, a key regulator of the glycolytic process.  The effects on the inhibition of 
glycolysis in ECs was evaluated by measuring their proliferation and migration capacity, as well as their ability to form 
neovessels. 
• Synthesis of K5, a bFGF inhibitor: 
 
 
 
 
 
 
 
 
• Scratch migration assay: to evaluate the 
migration  of ECs 
 
• MTT assay: to evaluate the proliferation  of ECs 
 
• Aortic ring assay: to evaluate ability of ECs to 
form neovessels 
